Navigation Links
Progenitor Cell Therapy Appoints VP of Manufacturing Operations
Date:7/13/2009

PCT Recruits Experienced Pharmaceutical Production Executive to Head its Two U.S. Contract Manufacturing Facilities

Hackensack, NJ (Vocus) July 13, 2009 -- Progenitor Cell Therapy, LLC (PCT) today announced the recent appointment of Daryl LeSueur as Vice President of Manufacturing Operations. As head of Manufacturing Operations, Daryl is responsible for managing and supervising the day-to-day conduct of the manufacturing, packaging, and operational functions of PCT’s two North American contract manufacturing facilities.

Daryl brings to PCT over 25 years of experience in manufacturing operations in FDA-regulated industries. His experience includes proven leadership and success in developing and implementing operational initiatives to promote quality, reduce production costs, increase profitability and enhance operational efficiencies.

Prior to joining PCT, Daryl served as Vice President, Operations, Pomona, East Hanover and Northvale for Barr Laboratories. Before joining Barr, Daryl served as Vice President of Pharmaceutical Production at Novartis Pharmaceutical Corporation. At Novartis, he was responsible for managing all North American production operations, specializing in solid dosage, raw material and transdermal systems, and oversaw a $70 million budget. Prior to Novartis, Daryl was Associate Director of Pharmaceutical Production with Sandoz Pharmaceutical Company.

Daryl has a B.S. in Chemistry from the State University of New York at Plattsburgh and has completed the Leadership Program, Finance Program, and Management Program at Harvard Business School.

“We are very pleased to add someone with the caliber of Daryl’s experience to our senior management team,” states PCT Chief Executive Officer, Dr. Andrew L. Pecora. “Bringing on seasoned executives who can ensure the highest quality service to our customers and execute our growth strategy is a critical component of our strategic plan”.

“Daryl’s experience with highly regulated pharmaceutical-grade production environments is a critical skill set to our commercial-quality service offering and is the kind of cross-sector recruitment that will be important to continue as regenerative medicine matures into a commercial sector”, adds PCT President and Chief Scientific Officer, Dr. Robert A. Preti.

About Progenitor Cell Therapy, LLC
Progenitor Cell Therapy, LLC (PCT) is a client-based company providing cell therapy service solutions for the research, development, manufacturing, and commercialization of cell-based therapies. With its cell therapy manufacturing facilities and team of experienced professionals, PCT provides current Good Manufacturing Practices (cGMP)-compliant services for pre-clinical and clinical development, manufacturing, and eventual commercialization of cellular therapies for clients throughout the world. For more information, please visit www.progenitorcelltherapy.com.

Disclaimer
This press release does not constitute an offer to sell, or a solicitation of any offer to buy any securities of Progenitor Cell Therapy. In addition, certain of the statements in this press release are forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research, and development activities and similar matters. These statements involve known and unknown risks, uncertainties, and other factors that may cause the company or its industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “intend,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of such terms or other comparable terminology. Forward-looking statements are only predictions. Actual events or results may differ materially. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither the company nor any other person assumes responsibility for the accuracy and completeness of such statements. The company is under no duty to update any of the forward-looking statements after the date of this press release to conform such statements to actual results.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2628514.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Progenitor Cell Therapy Secures Industry Accreditation
2. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
5. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
6. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
7. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
8. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
9. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
10. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
11. Stem Cell Therapy to Skyrocket by 2017
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Progenitor Cell Therapy Appoints VP of Manufacturing Operations
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
Breaking Biology News(10 mins):